MASS SPECTROMETRY OF ANTIGENIC LIPOPEPTIDES: HIV

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。所列机构为 中心，不一定是研究者的机构。 从一家商业公司获得了一种脂肽的合成版本，该脂肽是最早出现在HIV感染细胞中的化合物之一，并使用来自HIV患者供体的细胞来产生T细胞系。在进一步分析时，发现合成产生的靶向脂肽形式不是纯的，而实际上是混合物，并且进一步地，靶向脂肽不是抗原性的，而是发现两种新的组分是抗原性的。初步质谱研究表明，未知抗原组分在结构上彼此非常相似，并且具有与预期合成结构相似的部分结构。BUSM MS资源实验室的质谱研究包括使用MALDI和ESI Q-o-TOF和MALDI和ESI-FTMS仪器，以及已知和未知化合物的酶消化。结构现在已经解决，合成类似物正在制备中。 一张海报和一份手稿正在准备出版。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A synthetic version of a lipopeptide that is one of the first compounds to appear in HIV-infected cells was obtained from a commercial company and employed to generate a T cell line, using cells from an HIV patient donor. On further analysis it was found that the synthetically produced version of the targeted lipopeptide was not pure, but in fact a mixture, and further, the targeted lipopeptide was not antigenic, but instead two novel components were found to be antigenic. Preliminary mass spectrometric investigations indicated that the unknown antigenic components are very similar in structure to each other and have a partial structure similar to the intended synthetic structure. Mass spectrometric studies at the BUSM MS Resource laboratory have included the use of MALDI and ESI Q-o-TOF and MALDI and ESI-FTMS instrumentation, as well as the enzymatic digestion of the known and unknown compounds. The structure has now been solved and a synthetic analog is being prepared. A poster and a manuscript are being readied for publication.